AdipoRon

AdipoR agonist that binds to both AdipoR1 and AdipoR2.

Produced by adipocytes, adiponectin has circulating levels that are inversely related to the degree of adiposity. Adiponectin concentrations correlate negatively with glucose, insulin, triglyceride concentrations, liver fat content and body mass index, while correlating positively with high-density lipoprotein-cholesterol levels, hepatic insulin sensitivity and insulin-stimulated glucose disposal. Adiponectin controls many metabolic processes and is known to contribute to metabolic pathologies including diabetes, atherosclerosis, and obesity. It has been shown to increase insulin sensitivity and decrease plasma glucose by increasing tissue fat oxidation. Adiponectin receptor activation is a promising potential therapy for diabetes and other obesity-associated diseases. 

AdipoRon is a small-molecule adiponectin mimetic. At low micromolar concentrations, it binds to the adiponectin receptors AdipoR1 and AdipoR2. In addition, AdipoRon is orally administered and readily absorbed and delivered to target tissues, making it potentially clinically relevant. AdipoRon has been shown to induce insulin sensitivity, inhibit lipid synthesis and increase glucose metabolism.